HK1063721A1 - Quinolone carboxylic acid compositions and related methods of treatment - Google Patents

Quinolone carboxylic acid compositions and related methods of treatment

Info

Publication number
HK1063721A1
HK1063721A1 HK04106580.9A HK04106580A HK1063721A1 HK 1063721 A1 HK1063721 A1 HK 1063721A1 HK 04106580 A HK04106580 A HK 04106580A HK 1063721 A1 HK1063721 A1 HK 1063721A1
Authority
HK
Hong Kong
Prior art keywords
treatment
carboxylic acid
related methods
acid compositions
quinolone carboxylic
Prior art date
Application number
HK04106580.9A
Other languages
English (en)
Inventor
Samir Roy
Santosh Kumar Chandrasekaran
Katsumi Imamori
Takemitsu Asaoka
Akihiro Shibata
Masami Takahashi
Lyle M Bowman
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/840,871 external-priority patent/US6685958B2/en
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of HK1063721A1 publication Critical patent/HK1063721A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04106580.9A 2001-04-25 2004-09-01 Quinolone carboxylic acid compositions and related methods of treatment HK1063721A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/840,871 US6685958B2 (en) 2001-04-25 2001-04-25 Quinolone carboxylic acid compositions and related methods of treatment
US10/126,513 US6699492B2 (en) 1999-03-31 2002-04-22 Quinolone carboxylic acid compositions and related methods of treatment
PCT/US2002/012790 WO2002100309A1 (fr) 2001-04-25 2002-04-24 Compositions d'acide quinolone carboxylique et methodes de traitement associees

Publications (1)

Publication Number Publication Date
HK1063721A1 true HK1063721A1 (en) 2005-01-14

Family

ID=26824748

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106580.9A HK1063721A1 (en) 2001-04-25 2004-09-01 Quinolone carboxylic acid compositions and related methods of treatment

Country Status (8)

Country Link
US (2) US6699492B2 (fr)
EP (1) EP1395215B1 (fr)
JP (1) JP4994569B2 (fr)
KR (1) KR100927067B1 (fr)
AU (1) AU2002322002B2 (fr)
CA (1) CA2445408C (fr)
HK (1) HK1063721A1 (fr)
WO (1) WO2002100309A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699492B2 (en) * 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US7915085B2 (en) 2003-09-18 2011-03-29 Cree, Inc. Molded chip fabrication method
JP2010505861A (ja) 2006-10-06 2010-02-25 ボーシュ アンド ローム インコーポレイティド キノロンカルボン酸と、その誘導体と、これらの製造法および利用法
US8252783B2 (en) 2007-01-24 2012-08-28 Bausch & Lomb Incorporated Quinolone carboxylic acids, derivatives thereof, and methods of making and using same
US7632944B2 (en) * 2007-01-24 2009-12-15 Bausch & Lomb Incorporated Quinolone carboxylic acids, derivatives thereof, and methods of making and using same
US20080200442A1 (en) * 2007-02-16 2008-08-21 Srini Venkatesh Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections of the Ear or Upper Respiratory Tract
KR20130010131A (ko) * 2007-03-21 2013-01-25 보오슈 앤드 롬 인코포레이팃드 항박테리아 약물-내성 박테리아에 의해 유발되는 감염의 치료, 감소, 개선 또는 예방을 위한 플루오로퀴놀론
US20090054406A1 (en) * 2007-08-21 2009-02-26 Ward Keith W Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones
US20090082337A1 (en) * 2007-09-21 2009-03-26 Srini Venkastesh Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
KR20100067684A (ko) * 2007-11-05 2010-06-21 보오슈 앤드 롬 인코포레이팃드 약물 전달을 위한 비히클로서의 수불혼화성 물질
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
CN102026665A (zh) * 2008-05-19 2011-04-20 爱尔康研究有限公司 含有羧基乙烯基聚合物和聚维酮聚合物的药物组合物
WO2010096551A2 (fr) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Compositions antimicrobiennes
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US8481526B2 (en) * 2009-03-25 2013-07-09 Bausch & Lomb Incorporated Fluoroquinolone carboxylic acid molecular crystals
US10546846B2 (en) 2010-07-23 2020-01-28 Cree, Inc. Light transmission control for masking appearance of solid state light sources
US10568770B2 (en) 2015-05-07 2020-02-25 Kci Licensing, Inc. Controlled release iodine structure for use with wound care

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE375007B (fr) * 1972-11-30 1975-04-07 Pharmacia Ab
US4551456A (en) 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
EP0501523B1 (fr) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Compositions bioadhésives
US4692454A (en) 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5300296A (en) * 1989-11-06 1994-04-05 Frank J. Holly Antimicrobial agent for opthalmic formulations
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP2613139B2 (ja) 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
WO1993024460A1 (fr) 1992-05-26 1993-12-09 Ss Pharmaceutical Co., Ltd. Derive d'acides-5-aminoquinolonecarboxylique et agent antibacterien contenant ce derive comme ingredient actif
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
FR2706459B1 (fr) * 1993-06-17 1995-08-04 Bouchara Sa Nouveaux dérivés quinoloniques, leur procédé d'obtention et les compositions pharmaceutiques qui en contiennent.
EP0711147A1 (fr) * 1993-07-28 1996-05-15 Insite Vision Incorporated Suspensions servant a l'administration d'un medicament
US6309630B1 (en) 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
US5814655A (en) 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6159458A (en) 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6699492B2 (en) * 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial

Also Published As

Publication number Publication date
AU2002322002C1 (en) 2002-12-23
US20020182255A1 (en) 2002-12-05
JP4994569B2 (ja) 2012-08-08
KR100927067B1 (ko) 2009-11-13
EP1395215B1 (fr) 2014-03-19
US6699492B2 (en) 2004-03-02
EP1395215A1 (fr) 2004-03-10
KR20030092108A (ko) 2003-12-03
EP1395215A4 (fr) 2009-12-23
WO2002100309A1 (fr) 2002-12-19
JP2004529199A (ja) 2004-09-24
CA2445408A1 (fr) 2002-12-19
CA2445408C (fr) 2012-04-10
US20040157825A1 (en) 2004-08-12
AU2002322002B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
HK1063721A1 (en) Quinolone carboxylic acid compositions and related methods of treatment
TWI318878B (en) Quinolone carboxylic acid compositions and related methods of treatment
HK1080382A1 (en) Compositions and methods for treatment of hyperplasia
AU2002352726A8 (en) Formulations and methods for treatment or amelioration of inflammatory conditions
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
EP1461024A4 (fr) Traitement de plaies et compositions utilisees
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
EP1229930A4 (fr) Compositions et methodes pour le traitement des troubles allergiques
AU2002339696A8 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
EP1335736A4 (fr) Compositions et methodes de diagnostic et de traitement de troubles cardio-vasculaires
EP1461047A4 (fr) Compositions et techniques de traitement d'animaux
EP1416795A4 (fr) Compositions et procedes pour le traitement de maladies mitochondriales
EP1425027A4 (fr) Methode et composition pour le traitement de plaies et de brulures
IL145397A0 (en) Compositions and methods for treatment of cancer
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
IL156506A0 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EP1406572A4 (fr) Formulation pediatrique de gatifloxacine
GB0124124D0 (en) Methods of treatment
GB0324523D0 (en) Compositions and methods of treatment
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
GB2399500B (en) Composition and method for treatment of wounds
TJ20010671A (en) Method of treatment of diseases of parodont of abscess formation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210424